- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
The Pharma Top 20s
Next >
Top 25 US Products by Sales: Lipitor clung on to the top spot but increasingly feels the impact of generic competition.
Top 20 Global Products: Biologics are increasing apace among the top product offerings, accounting for eight of the 20 biggest selling drugs.
Top 20 Global Therapeutic Classes: The surge in antidiabetics clearly reflects the consequences of lifestyle changes that are edging around the world.
Top 25 Corporations by US Sales: Pfizer holds on at home despite falling Lipitor sales, but the loss of the Lipitor patent at the end of 2011 will make this lead increasingly tenuous.
Top 25 Corporations by US Prescriptions: Increased prescribing of generics saw Watson, Amneal and Lupin Laboratories surge ahead in 2011.
Major patent expiries in 2012.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
